secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001396814-24-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports preliminary FY2023 revenue of $675.0M, up 1.2% YoY; Q4 EXPAREL sales $143.9M
--------------------------------------------------------------------------------

- FY2023 total revenue $675.0M vs $666.8M in FY2022, driven by EXPAREL ($538.1M), ZILRETTA ($111.1M), iovera° ($19.7M).
- Q4 2023 EXPAREL net sales $143.9M (+4.3% YoY); ZILRETTA $28.7M (+2.5%); iovera° $6.0M (+30%).
- ExPAREL full-year average daily volume growth of 5%, offset by lower net selling price from 340B and other contracts.
- Company plans to launch EXPAREL in two lower extremity nerve blocks in 2024 and expects NOPAIN Act expansion in 2025.
- Preliminary, unaudited figures; complete Q4/FY results with 2024 guidance expected in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/pcrx-20240104.htm
  HTML page:      https://secwatch.observer/filing/0001396814-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer